| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3edb9aa141cda1fdc8cb548d0c57f59c |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-547
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-635
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4375
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-34
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-10 |
| filingDate |
2020-05-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1b9dc6576e0cf3659a6484ab6187ed2b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7619e0a60f855e8fae3f4912ff547fbd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b9e6531d93a80733e50699efd5b886d8 |
| publicationDate |
2020-12-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020237392-A1 |
| titleOfInvention |
Methods for treatment of b cell related cancers by inhibition of pkn1 |
| abstract |
The present application provides methods and compositions for treatment of B cell related cancers by inhibition of PKN1. The method for treating a B cell related cancer, such as Chronic Lymphocytic Leukemia (CLL) comprises administering a protein kinase C related kinase (PKN1) inhibitor or a pharmaceutically acceptable salt or solvate thereof. The method for treating the B cell related cancer can include administering the PKN1 inhibitor in combination with a Bcl-2 antagonist, such as venetoclax. Also provided is a method for determining whether a subject is susceptible to venetoclax resistance comprising measuring the level of TRAF1 expression in the subject's cancer cells. |
| priorityDate |
2019-05-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |